Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) shares fell 4.7% on Monday . The stock traded as low as $33.39 and last traded at $33.6980. 63,269 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 345,553 shares. The stock had previously closed at $35.37.
Analyst Ratings Changes
Several brokerages have weighed in on SION. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Citigroup began coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. BTIG Research reiterated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, May 13th. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Finally, Citizens Jmp reissued a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.22.
Read Our Latest Stock Report on SION
Sionna Therapeutics Trading Up 0.5%
Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, analysts predict that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the sale, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,717,962 shares of company stock worth $77,571,889. 5.10% of the stock is currently owned by corporate insiders.
Institutional Trading of Sionna Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in Sionna Therapeutics by 16.8% during the 1st quarter. Bank of America Corp DE now owns 50,870 shares of the company’s stock worth $2,039,000 after purchasing an additional 7,303 shares during the period. Stempoint Capital LP purchased a new stake in Sionna Therapeutics during the 1st quarter worth $1,465,000. Walleye Capital LLC purchased a new stake in Sionna Therapeutics during the 1st quarter worth $605,000. AlphaCentric Advisors LLC boosted its position in Sionna Therapeutics by 77.1% during the 1st quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after purchasing an additional 2,098 shares during the period. Finally, Jennison Associates LLC boosted its position in Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the period.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- Synchrony’s Comeback Is Hiding in Plain Sight
- Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
